CNS Pharmaceuticals, Inc.

The momentum for this stock is not very good. CNS Pharmaceuticals, Inc. is not a good value stock. CNS Pharmaceuticals, Inc. is not a good growth stock. CNS Pharmaceuticals, Inc. is a mediocre stock to choose.

News

CNS Pharmaceuticals Regains Compliance with Nasdaq Equity Requirement

Accesswire HOUSTON, TX / ACCESSWIRE / September 12, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ('CNS' or the 'Company'), a biopharmaceutical company specializing in the development of novel treatments for...\n more…

CNS Pharmaceuticals (NASDAQ:CNSP) Rating Increased to Buy at Maxim Group

Ticker Report CNS Pharmaceuticals (NASDAQ:CNSP - Get Free Report) was upgraded by investment analysts at Maxim Group from a "hold" rating to a "buy" rating in a research report issued on Tuesday, Benzinga reports...\n more…

CNS Pharmaceuticals (NASDAQ:CNSP) Stock Rating Upgraded by Maxim Group

Zolmax CNS Pharmaceuticals (NASDAQ:CNSP - Get Free Report) was upgraded by equities researchers at Maxim Group from a "hold" rating to a "buy" rating in a report issued on Tuesday, Benzinga reports. The...\n more…

Maxim upgrades CNS Pharmaceuticals to Buy after equity raise

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

CNS Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Accesswire HOUSTON, TX / ACCESSWIRE / September 4, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ('CNS' or the 'Company'), a biopharmaceutical company specializing in the development of novel treatments for...\n more…

IBN Announces Latest Episode of The BioMedWire Podcast featuring John Climaco, CEO of CNS Pharmaceuticals Inc.

Globe Newswire LOS ANGELES, Sept. 03, 2024 (GLOBE NEWSWIRE) -- via IBN IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce...\n more…